FMP
Resverlogix Corp.
RVX.TO
TSX
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
0.04 CAD
-0.005 (-12.5%)
Balance Sheet
Year
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Total Cash
10.87M
5.66k
123
8.48k
56.55k
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
1.38M
1.3M
-
438.29k
456.67k
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
1.63M
2.2M
825.68
3.47M
3.35M
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
11.58M
11.14M
9.81k
12.3M
19.93M
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-879.4k
-706.91k
-18.38
-1.24M
-636.22k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
